

Approved



Swaziland
Country Operational Plan
FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,017,400		1,017,400	0	1,017,400
USAID		25,796,285	6,900,000	32,696,285	1,509,806	34,206,091
DOD		547,690		547,690	433,661	981,351
PC		1,067,266		1,067,266	0	1,067,266
HHS/CDC	487,500	13,149,380		13,636,880	2,789,012	16,425,892
State/AF		102,000		102,000	0	102,000
Total	487,500	41,680,021	6,900,000	49,067,521	4,732,479	53,800,000

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	DOD	HHS/CDC	PC	State/AF	USAID		
CIRC	2,117	2,472	3,571			3,682,574	0	3,690,734
HBHC	95,204	110,703	2,079,706		102,000	3,876,855	0	6,264,468
HKID	37,667		0	771,259		3,843,348	0	4,652,274
HLAB	0	2,472	40,154				0	42,626
HMBL	0		1,786				0	1,786
HMIN	0						0	0
HTXD	2,117					5,826,594	0	5,828,711
HTXS	154,018	150,966	5,398,480		0	7,172,795	0	12,876,259
HVAB	9,306			27,581		1,723	0	38,610
HVCT	27,522	100,173	1,702,832			981,035	0	2,811,562
HVMS	540,855	25,393	980,488	224,620		991,426	0	2,762,782
HVOP	26,243	77,442	1,786	21,092		2,566,025	0	2,692,588

Approved



HVSI	40,225	60,000	956,077			266,453	0	1,322,755
HVTB	2,117	10,652	1,511,163		0	999,742	0	2,523,674
IDUP	0						0	0
MTCT	27,522		414,555			1,016,200	0	1,458,277
OHSS	24,965	7,417	87,972	22,714		650,795	0	793,863
PDCS	25,405		5,357			384,083	0	414,845
PDTX	2,117		452,953		0	436,637	0	891,707
	1,017,400	547,690	13,636,880	1,067,266	102,000	32,696,285	0	49,067,521



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	6,110,374	0
HKID	3,875,249	0
HVTB	2,441,844	0
PDCS	379,907	0
Total Technical Area Planned Funding:	12,807,374	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	0	0
HVSI	1,010,947	0
OHSS	606,639	0
Total Technical Area Planned Funding:	1,617,586	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	3,670,513	0
HMBL	0	0
HVAB	0	0
HVCT	2,653,377	0
HVOP	2,627,455	0
MTCT	1,411,073	0
Total Technical Area Planned Funding:	10,362,418	0

Approved



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	5,821,426	0
HTXS	12,224,036	0
PDTX	833,930	0
Total Technical Area Planned Funding:	18,879,392	0

Technical Area Summary Indicators and Targets

Indicator Number	Label	2017
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,502
	Number of new ANC and L&D clients	29,941
	By: Known positives at entry	6,236
	By: Number of new positives identified	3,613
	Sum of Positives Status disaggregates	9,849
	Required only for DREAMS Countries - By Number of new positives: <15	38
	Required only for DREAMS Countries - By Number of new positives: 15-19	423
	Required only for DREAMS Countries - By Number of new positives: 20-24	878
	Required only for DREAMS Countries - By Number of known positives: <15	64
	Required only for DREAMS Countries - By Number of known	641



	positives: 15-19	
	Required only for DREAMS Countries - By Number of known positives: 20-24	1,261
	Required only for DREAMS Countries - Denominator: <15	358
	Required only for DREAMS Countries - Denominator: <15-19	3,775
	Required only for DREAMS Countries - Denominator: 20-24	6,696
	Required only for DREAMS Countries - Denominator: 25-49	10,380
	Required only for DREAMS Countries - Denominator: 50+	299
	Required only for DREAMS Countries - By Number of known positives: 25-49	2,527
	Required only for DREAMS Countries - By Number of known positives: 50+	59
	Required only for DREAMS Countries - By Number of new positives: 25-49	1,263
	Required only for DREAMS Countries - By Number of new positives: 50+	37
	By Age (DREAMS SNUs ONLY): <15	309
	By Age (DREAMS SNUs ONLY): 15-19	3,569
	By Age (DREAMS SNUs ONLY): 20-24	6,341
	By Age (DREAMS SNUs ONLY): 25-49	10,039



	By Age (DREAMS SNU's ONLY): 50+	257
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	872
	Number of new ANC and L&D clients	955
	By: Known positives at entry	213
	By: Number of new positives identified	116
	Sum of Positives Status disaggregates	329
	Required only for DREAMS countries - By known positives: <15	3
	Required only for DREAMS countries - By known positives: 15-19	20
	Required only for DREAMS countries - By known positives: 20-24	45
	Required only for DREAMS countries - By new positives: <15	1
	Required only for DREAMS countries - By new positives: 15-19	14
	Required only for DREAMS countries - By new positives: 20-24	31
	Required only for DREAMS countries - Denominator: <15	13



	Required only for DREAMS countries - Denominator: 15-19	121
	Required only for DREAMS countries - Denominator: 20-24	237
	Required only for DREAMS countries - Denominator: 25-49	427
	Required only for DREAMS countries - Denominator: 50+	17
	Required only for DREAMS countries - By known positives: 25-49	116
	Required only for DREAMS countries - By known positives: 50+	2
	Required only for DREAMS countries - By new positives: 25-49	52
	Required only for DREAMS countries - By new positives: 50+	1
	By Age (DREAMS SNU's ONLY): <15	15
	By Age (DREAMS SNU's ONLY): 15-19	112
	By Age (DREAMS SNU's ONLY): 20-24	207
	By Age (DREAMS SNU's ONLY): 25-49	393
	By Age (DREAMS SNU's ONLY): 50+	12
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	



	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,502
	New on ART	4,261
	Already on ART at beginning of current pregnancy	4,927
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	n/a
	Number of HIV-positive pregnant women who	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	872
	New on ART	154
	Already on ART at beginning of current pregnancy	183
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	18,616
	By Age: 0-60 days	0
	By Age: 2 months - 9 years	0
	By Age: 10-14	4,418
	By Age: 15-19	9,291
	By Age: 20-24	2,508
	By Age: 25-29	1,629
	By Age: 30-49	751
	By Age: 50+	19



	Sum of age disaggregates (Prior to FY15)	16,236
	Sum of age disaggregates (FY15-Current)	18,616
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	18,586
	By circumcision technique: Device-based VMMC	0
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have received antiretroviral preexposure	329



	Male 10-14	
	Male 15-19	
	Male 20-24	
	Male 25-49	
	Male 50+	
	Female 10-14	
	Female 15-19	
	Female 20-24	329
	Female 25-49	
	Female 50+	
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	107,816
	Total number of people in the target population	200,640
	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	



	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	0
	Aggregated Age/sex: 15+ Male	46,319
	Aggregated Age/sex: <15 Female	14,967
	Aggregated Age/sex: 15+ Female	46,530
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	7,900



	required	
	Total estimated number of key population in the catchment area	12,573
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,960
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Female	5,940



	<p>sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)</p>	
	<p>By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)</p>	



	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	2,519
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	10,054
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	



	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: REturniong beneficiary within the current report period	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	230,657
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	4,203
	Age/sex: 15-19 Male	10,967
	Age/sex: 20-24 Male	15,375
	Age/sex: 25-49 Male	47,614
	Age/sex: 50+ Male	4,240
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	2,751
	Age/sex: 15-19 Female	15,585
	Age/sex: 20-24 Female	24,821
	Age/sex: 25-49 Female	27,238
	Age/sex: 50+ Female	4,733
	Test Result by Age and Sex: Positive: 10-14 Male	265
	Test Result by Age and Sex: Positive: 15-19 Male	850
	Test Result by Age and Sex: Positive: 20-24 Male	1,369
Test Result by Age and Sex: Positive: 25-49 Male	5,053	
Test Result by Age and Sex:	300	



	Positive: 50+ Male	
	Test Result by Age and Sex: Positive: 10-14 Female	290
	Test Result by Age and Sex: Positive: 15-19 Female	1,570
	Test Result by Age and Sex: Positive: 20-24 Female	2,720
	Test Result by Age and Sex: Positive: 25-49 Female	3,357
	Test Result by Age and Sex: Positive: 50+ Female	364
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	22,718
	Aggregated Age/sex - USE WITH	102,488



HQ PERMISSION ONLY: 15+ Male	
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	9,882
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	95,565
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	813
Test Result by Aggregated Age and Sex: Positive 15+ Male	10,125
Test Result by Aggregated Age and Sex: Positive <15 Female	684
Test Result by Aggregated Age and Sex: Positive 15+ Female	11,487
Test Result by Age: Positive: <1	119
Test Result by Age: Positive: 1-9	364
Age/sex: <1	4,426
Age/sex: 1-9	8,203
Service Delivery Point (Community): Index testing	7,498
Service Delivery Point (Community): Homebased testing	4,852
Service Delivery Point (Community): Mobile testing	63,226
Service Delivery Point	4,145



	(Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	2,665
	Service Delivery Point (Facility): Outpatient	62,781
	Service Delivery Point (Facility): Pediatric	15,378
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	10,030
	Service Delivery Point (Facility): VCT	16,051
	Service Delivery Point (Facility): VMMC	14,759
	Service Delivery Point (Facility): PMTCT	24,206
	Service Delivery Point (Facility): TB	1,408



	Clinics	
	Service Delivery Point (Facility): Index testing	3,657
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatroc	
	Service Delivery Point (Facility) by Age: >15 Pediatroc	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	
	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by	



	Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,473
	Age/sex: 5-9 Male	
	Age/sex: 10-14 Male	25
	Age/sex: 15-19 Male	229
	Age/sex: 20-24 Male	569
	Age/sex: 25-49 Male	1,358
	Age/sex: 50+ Male	273
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	20
	Age/sex: 15-19 Female	269
	Age/sex: 20-24 Female	593
	Age/sex: 25-49 Female	1,168
	Age/sex: 50+ Female	207
	Test Result by Age and Sex: Positive: 10-14 Male	1
	Test Result by Age and Sex: Positive: 15-19 Male	21
Test Result by Age and Sex: Positive: 20-24 Male	63	
Test Result by Age and Sex: Positive: 25-49 Male	144	



	Test Result by Age and Sex: Positive: 50+ Male	30
	Test Result by Age and Sex: Positive: 10-14 Female	1
	Test Result by Age and Sex: Positive: 15-19 Female	25
	Test Result by Age and Sex: Positive: 20-24 Female	64
	Test Result by Age and Sex: Positive: 25-49 Female	147
	Test Result by Age and Sex: Positive: 50+ Female	19
	Test Result by Age and Sex: Negative: 10-14 Male	
	Test Result by Age and Sex: Negative: 15-19 Male	
	Test Result by Age and Sex: Negative: 20-24 Male	
	Test Result by Age and Sex: Negative: 25-49 Male	
	Test Result by Age and Sex: Negative: 50+ Male	
	Test Result by Age and Sex: Negative: <1 Female	
	Test Result by Age and Sex: Negative: 10-14 Female	
	Test Result by Age and Sex: Negative: 15-19 Female	
	Test Result by Age and Sex: Negative: 20-24 Female	
	Test Result by Age and Sex: Negative: 25-49 Female	
	Test Result by Age and Sex: Negative: 50+ Female	



Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	597
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	2,882
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	326
Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,668
Test Result by Aggregated Age and Sex: Negative <15 Male	
Test Result by Aggregated Age and Sex: Negative 15+ Male	
Test Result by Aggregated Age and Sex: Negative <15 Female	
Test Result by Aggregated Age and Sex: Negative 15+ Female	
Test Result by Aggregated Age and Sex: Positive <15 Male	11
Test Result by Aggregated Age and Sex: Positive 15+ Male	301
Test Result by Aggregated Age and Sex: Positive <15 Female	19
Test Result by Aggregated Age and Sex: Positive 15+ Female	309
Test Result by Age: Positive: <1	7
Test Result by Age: Positive: 1-9	19
Age/sex: <1	298
Age/sex: 1-9	420
Service Delivery Point (Community): Index testing	
Service Delivery Point (Community): Homebased testing	



	Service Delivery Point (Community): Mobile testing	
	Service Delivery Point (Community): Other	
	Service Delivery Point (Community) by Age: <15 index testing	
	Service Delivery Point (Community) by Age: 15+ index testing	
	Service Delivery Point (Community) by Age: <15 homebased testing	
	Service Delivery Point (Community) by Age: 15+ homebased testing	
	Service Delivery Point (Community) by Age: <15 mobile testing	
	Service Delivery Point (Community) by Age: 15+ mobile testing	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Community) by Age: <15 other	
	Service Delivery Point (Facility): Inpatient	14
	Service Delivery Point (Facility): Outpatient	3,785
	Service Delivery Point (Facility): Pediatric	658
	Service Delivery Point (Facility): Malnutrition facilities	0
	Service Delivery Point (Facility): Other PITC	212
	Service Delivery Point (Facility): VCT	638
	Service Delivery Point (Facility): VMMC	0



	Service Delivery Point (Facility): PMTCT	991
	Service Delivery Point (Facility): TB Clinics	47
	Service Delivery Point (Facility): Index testing	128
	Service Delivery Point (Facility) by Age: <15 Inpatient	
	Service Delivery Point (Facility) by Age: >15 Inpatient	
	Service Delivery Point (Facility) by Age: <15 Outpatient	
	Service Delivery Point (Facility) by Age: >15 Outpatient	
	Service Delivery Point (Facility) by Age: <15 Pediatric	
	Service Delivery Point (Facility) by Age: >15 Pediatric	
	Service Delivery Point (Facility) by Age: <15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: >15 Malnutrition facilities	
	Service Delivery Point (Facility) by Age: <15 Other PITC	
	Service Delivery Point (Facility) by Age: >15 Other PITC	
	Service Delivery Point (Facility) by Age: <15 VCT	
	Service Delivery Point (Facility) by Age: >15 VCT	
	Service Delivery Point (Facility) by Age: <15 VMMC	
	Service Delivery Point (Facility) by Age: >15 VMMC	



	Service Delivery Point (Facility) by Age: <15 PMTCT	
	Service Delivery Point (Facility) by Age: >15 PMTCT	
	Service Delivery Point (Facility) by Age: <15 TB Clinics	
	Service Delivery Point (Facility) by Age: >15 TB Clinics	
	Service Delivery Point (Facility) by Age: <15 Index testing	
	Service Delivery Point (Facility) by Age: >15 Index testing	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,981
	Total number of registered new and relapsed TB cases, during the reporting period.	6,249
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	185
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,910
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	202
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,685
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	



	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	



	cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
	Number of registered new and	59



	relapsed TB cases with documented HIV status, during the reporting period.	
	Total number of registered new and relapsed TB cases, during the reporting period.	60
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator:	



	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered	44



	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,647
	Age/Sex: <10 Male	33
	Age/Sex: 10-14 Male	48
	Age/Sex: 15-17 Male	
	Age/Sex: 18-19 Male	
	Age/Sex: 20-24 Male	57
	Age/Sex: 25-49 Male	164



	Age/Sex: 50+ Male	26
	Age/Sex: <10 Female	168
	Age/Sex: 10-14 Female	185
	Age/Sex: 15-17 Female	
	Age/Sex: 18-19 Female	
	Age/Sex: 20-24 Female	203
	Age/Sex: 25-49 Female	404
	Age/Sex: 50+ Female	118
	Sum of Age/Sex Disaggregates	434
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,042
	By type of service: Sexual Violence (Post-Rape Care)	605
	By PEP service provision (related to sexual violence services provided)	331
	Age/Sex: 15-19 Female	188
	Age/Sex: 15-19 male	53
GEND_GB_V_TA	Number of people receiving post-GBV care	227
	Age/Sex: <10 Male	6
	Age/Sex: 10-14 Male	9
	Age/Sex: 20-24 Male	7
	Age/Sex: 25-49 Male	27
	Age/Sex: 50+ Male	5
	Age/Sex: <10 Female	24
	Age/Sex: 10-14 Female	26
	Age/Sex: 20-24 Female	23
	Age/Sex: 25-49 Female	54
	Age/Sex: 50+ Female	13
	Sum of Age/Sex Disaggregates	65
	By type of service: Physical and/or	130



	Emotional Violence (Other Post-GBV Care)	
	By type of service: Sexual Violence (Post-Rape Care)	97
	By PEP service provision (related to sexual violence services provided)	44
	Age/Sex: 15-19 Female	24
	Age/Sex: 15-19 Male	9
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	57,338
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By: Age/sex: Male 18-24	
	By: Age/sex: Male 25+	
	Age/Sex: 18+ Male	136
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By: Age/sex: 18-24 Female	
	By: Age/sex: 25+ Female	
	Age/Sex: 18+ Female	263
	Sum of Age/Sex disaggregates	399
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	3,516
	Required only for DREAMS countries - By service, age and sex: Education Support Female	4,581



	15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,641
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	2,453
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	2,331
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	3,403



	Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,569
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,779
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female	1,482



	10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,278
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	398
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	327
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	2,298



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,027
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,134
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,173
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	



	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	4,025
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	4,541
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,924
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1,994
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	



	Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	
	Program Completion: Graduation	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	By Aggregated Age/Sex: <18 Male	21,189
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	35,531
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	



	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,195
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	4,709
	Age/Sex: >1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented	



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of	



	registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	124
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented	2,072



	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	132
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,877
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Aggregated Age/Sex: Male 15+</p>	



	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	36
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	39
	Age/Sex: <1 (Numerator: The number of registered new and	



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and	



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on	



	ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	25
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB	



	treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	



	<p>Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)</p>	
	<p>Age/Sex: Female 50+ (Denominator: The number of</p>	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility	148,555



	during the reporting period.	
	Screened for TB by Age/Sex: <15 Male	4,915
	Screened for TB by Age/Sex: 15+ Male	50,773
	Screened for TB by Age/Sex: <15 Female	5,717
	Screened for TB by Age/Sex: 15+ Female	87,059
	Screen Result: Screened Positive for TB	10,466
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	9,098
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	9,009
	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	90
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	1,505
	Screened for TB by Age/Sex: <15 Male	31
	Screened for TB by Age/Sex: 15+	701



	Male	
	Screened for TB by Age/Sex: <15 Female	34
	Screened for TB by Age/Sex: 15+ Female	730
	Screen Results: Screened Positive for TB	112
	TB Positive by Age/Sex: <15 Male	
	TB Positive by Age/Sex: 15+ Male	
	TB Positive by Age/Sex: <15 Female	
	TB Positive by Age/Sex: 15+ Female	
	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	100
	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	100
	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	1
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into	



	PMTCT)	
	By infants who received a virologic test within 2 months of birth	8,660
	By infants who received their first virologic HIV test between 2 and 12 months of age	721
	Sum of Infant Age disaggregates	9,381
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	257
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	62
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into	



	PMTCT)	
	By infants who received a virologic test within 2 months of birth	305
	By infants who received their first virologic HIV test between 2 and 12 months of age	33
	Sum of Infant Age disaggregates	338
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	10
	Number of infants with a negative virological test result within 2 months of birth	
	Number of infants with a positive virological test result between 2 and 12 months of birth	
	Number of infants with a negative virological test result between 2 and 12 months of birth	
	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	151,058
	Age/Sex: 15-19 Male	641
	Age/Sex: 15-19 Female	2,948
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	4,353
	Aggregated Age/Sex: 15+ Male	46,626



	Aggregated Age/Sex: <15 Female	5,640
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	94,585
	Sum of Aggregated Age/Sex <15	9,993
	Sum of Aggregated Age/Sex 15+	141,211
	Sum of Aggregated Age/Sex disaggregates	151,204
	Age/Sex: <1	1,663
	Age/Sex: <1-9	3,349
	Age/Sex: 10-14 Male	1,154
	Age/Sex: 10-14 Female	1,032
	Aggregated Age/Sex: 1-14 Male	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	1,379
	Age/Sex: 25-49 Male	27,114
	Age/Sex: 50+ Male	5,897
	Age/Sex: 20-24 Female	10,135
	Age/Sex: 25-49 Female	51,315
	Age/Sex: 50+ Female	7,639
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,508
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	4
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	31



	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	35
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	36
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	530
	Aggregated Age/Sex: <15 Female	43
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	899
	Sum of Aggregated Age/Sex <15	79
	Sum of Aggregated Age/Sex 15+	1,429
	Sum of Aggregated Age/Sex disaggregates	1,508
	Age/Sex: <1	26
	Age/Sex: 1-9	15
	Age/Sex: 10-14 Male	7
	Age/Sex: 10-14 Female	9
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	22
	Age/Sex: 25-49 Male	359
	Age/Sex: 50+ Male	40
	Age/Sex: 20-24 Female	150
	Age/Sex: 25-49 Female	447
	Age/Sex: 50+ Female	109
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	29,506
	By Age/Sex: <1	415
	By Age/Sex: 1-9	454
	By Age/Sex: 10-14 Male	168



	By Age/Sex: 15-19 Male	78
	By Age/Sex: 20-24 Male	282
	By Age/Sex: 25-49 Male	4,450
	By Age/Sex: 50+ Male	723
	By Age/Sex: 10-14 Female	158
	By Age/Sex: 15-19 Female	842
	By Age/Sex: 20-24 Female	2,806
	By Age/Sex: 25-49 Female	8,261
	By Age/Sex: 50+ Female	816
	Sum of Age/Sex disaggregates	18,584
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	952
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	8,162
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	962
	Aggregated Grouping by Age/Sex: 15+ Female	19,240
	Sum of Aggregated Age/Sex disaggregates	29,316
	Pregnancy status	
	Breastfeeding status	
	Aggregated Grouping by Age/Sex: 1-14 Female	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral	946



	therapy (ART)	
	By Age/Sex: <1	
	By Age/Sex: 1-9	16
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	4
	By Age/Sex: 15-19 Male	3
	By Age/Sex: 20-24 Male	13
	By Age/Sex: 25-49 Male	193
	By Age/Sex: 50+ Male	27
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	4
	By Age/Sex: 15-19 Female	29
	By Age/Sex: 20-24 Female	109
	By Age/Sex: 25-49 Female	301
	By Age/Sex: 50+ Female	38
	Sum of Age/Sex disaggregates	721
	Aggregated Grouping by Age: <1	23
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	30
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	289
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	31



	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	596
	Sum of Aggregated Age/Sex disaggregates	946
	Pregnancy status	
	Breastfeeding status	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	111,511
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	137,046
	Numerator: Indication: Routine	92,392
	Numerator: Indication: Targeted	19,120
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Numerator: Preg/BF by Indication:	



	Breastfeeding Targeted	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication:	



	20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Denominator: Indication: Routine	113,226
	Denominator: Indication: Targeted	23,820
	Denominator: Preg/BF by	



	Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by	



	Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex	



	by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator Aggregated Age/Sex: <15 Male	3,652
	Numerator Aggregated Age/Sex: 15+ Male	39,273
	Numerator Aggregated Age/Sex: <15 Female	4,321
	Numerator Aggregated Age/Sex: 15+ Female	64,265
	Denominator Aggregated Age/Sex: <15 Male	4,583
	Denominator Aggregated Age/Sex: 15+ Male	48,717
	Denominator Aggregated Age/Sex: <15 Female	5,372
	Denominator Aggregated Age/Sex: 15+ Female	78,372
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	n/a
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	936
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical	1,132



	record and /or laboratory records in the past 12 months.	
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	



	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Numerator: Indication: Routine	750
	Numerator: Indication: Targeted	186



	Numerator: Preg/BF by Indication: Breastfeeding Routine	
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	
	Numerator: Preg/BF by Indication: Pregnant Routine	
	Numerator: Preg/BF by Indication: Pregnant Targeted	
	Denominator: Indication: Routine	899
	Denominator: Indication: Targeted	233
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	



	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	



	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	
	Denominator: Preg/BF by Indication: Breastfeeding Routine	
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	
	Denominator: Preg/BF by Indication: Pregnant Routine	
	Denominator: Preg/BF by Indication: Pregnant Targeted	
	Numerator Aggregated Age/Sex: <15 Male	20
	Numerator Aggregated Age/Sex: 15+ Male	393
	Numerator Aggregated Age/Sex: <15 Female	23
	Numerator Aggregated Age/Sex: 15+ Female	500
	Denominator Aggregated Age/Sex: <15 Male	23
	Denominator Aggregated Age/Sex: 15+ Male	467
	Denominator Aggregated Age/Sex: <15 Female	28
	Denominator Aggregated Age/Sex: 15+ Female	614
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	21,581
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	23,607
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	332
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	366
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	140
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	60
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	226
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,652
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	576



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	108
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	643
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,296
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,974
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	678
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	357
	Age/Sex: 1-9 (Denominator: Total number of adults and children who	400



	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	154
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	274
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those who have stopped ART, and	3,980



	those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	626
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	126
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	706
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,514
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated	7,604



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	737
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	



	those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	892
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,342
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,421
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12,927
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	965



	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,943
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,547
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14,152
TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	337
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	369



	stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3



	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	94
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated	3



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	56
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to	2



	follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	104
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated	4



	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	
	Numerator by Status: Breastfeeding	
	Denominator by Status: Pregnant	
	Denominator by Status: Breastfeeding	



	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	96
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102



	<p>Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>8</p>
	<p>Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)</p>	<p>248</p>
<p>LAB_PT_DSD</p>	<p>Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program</p>	
	<p>HIV serologic/diagnostic testing: Number of laboratories that perform this testing</p>	<p>57</p>
	<p>HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program</p>	<p>57</p>
	<p>HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program</p>	<p>51</p>
	<p>CD4: Number of laboratories that perform this testing</p>	<p>57</p>
	<p>CD4: Number of laboratories that participate in this PT program</p>	<p>57</p>



	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	51
	Early infant diagnostics: Number of laboratories that perform this testing	1
	Early infant diagnostics: Number of laboratories that participate in this PT program	1
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	15
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	15
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	14
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that	15



	perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	15
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	14
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	
	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	16
	CD4: Number of laboratories that participate in this PT program	18
	CD4: Number of laboratories that perform this testing	34
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0



	Early infant diagnostics: Number of laboratories that participate in this PT program	0
	Early infant diagnostics: Number of laboratories that perform this testing	0
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	66
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	73
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	93
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
	HIV viral load: Number of laboratories that participate in this PT program	1
	HIV viral load: Number of laboratories that perform this testing	1
	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	11
	TB diagnostics (AFB microscopy): Number of laboratories that	11



	perform this testing	
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	11
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	11
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	339
	By Graduates: Doctors	0
	By Graduates: Nurses	145
	By Graduates: Midwives	85
	By Graduates: Social service workers	0
	By Graduates: Laboratory professionals	21
	By Graduates: Other	88



	Sum of Graduates disaggreagtes	339
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	2
	Number of HIV Test Kits purchased	0
	Number of HIV CD4 Reagents purchased	0
	Number of Condoms purchased	0
	Number of HIV Viral Load Reagents purchased	0
	Number of HIV ARVs purchased	0
	Number of Second Line HIV ARVs purchased	
	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	547,441
	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	0
	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	0
	Condoms: Dollars planned (COP)/ spent (Actual)	0
	HIV ARVs: Dollars planned (COP)/ spent (Actual)	5,573,985



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10157	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	0
10247	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10694	Ministry of Health and Social Welfare, Swaziland	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GAP, GHP-State	0
10695	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10703	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
11673	U.S. Department	Other USG	U.S. Department	GHP-State	0



	of Defense (Defense)	Agency	of Defense		
13144	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13630	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
13645	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	0
13738	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13742	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	0
13791	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14201	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	1,119,359



14374	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14437	World Health Organization	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
14842	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	51,000
16760	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-USAID	0
16812	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16815	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	0
16821	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-USAID	1,726,894
17096	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
17389	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	67,821



17454	Centre for HIV and AIDS Prevention Studies Swaziland	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	3,121,835
17455	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	51,000
17458	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	700,000
17460	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,028,714
17461	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,754,921
17462	Ministry of Health and Social Welfare, Swaziland	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	153,055
17463	International	University	U.S. Department	GHP-State	4,760,862



	Center for AIDS Care and Treatment Programs, Columbia University		of Health and Human Services/Centers for Disease Control and Prevention		
17464	Pact	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	4,728,202
17465	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	6,408,846
17548	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	0
17555	VISTA PARTNERS	Implementing Agency	U.S. Department of Defense	GHP-State	0
17559	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	0
17572	American Association of Blood Banks	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17775	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
17965	Catholic Relief Services	FBO	U.S. Agency for International Development	GHP-State	795,742
17966	Population	NGO	U.S. Agency for	GHP-State	761,690



	Services International		International Development		
17967	TBD	TBD	Redacted	Redacted	Redacted
17972	Measure Evaluation	NGO	U.S. Agency for International Development	GHP-State	200,000
18169	TBD	TBD	Redacted	Redacted	Redacted
18250	WHO/AFRO	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	500,000
18272	TBD	TBD	Redacted	Redacted	Redacted
18329	TBD	TBD	Redacted	Redacted	Redacted
18331	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	6,166,486
18379	TBD	TBD	Redacted	Redacted	Redacted
18380	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	0
18387	FHI 360	NGO	U.S. Agency for International Development	GHP-USAID	594,902



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10157	Mechanism Name: PACT
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0
GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10157		
Mechanism Name:	PACT		
Prime Partner Name:	Pact, Inc.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 10247	Mechanism Name: ICAP/CDC: Improving Quality of Treatment Services
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10247		
Mechanism Name:	ICAP/CDC: Improving Quality of Treatment Services		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10694	Mechanism Name: MOH Capacity Building
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Swaziland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GAP	0
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10694		
Mechanism Name:	MOH Capacity Building		
Prime Partner Name:	Ministry of Health and Social Welfare, Swaziland		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10695	Mechanism Name: ICAP/UTAP
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10695		
Mechanism Name:	ICAP/UTAP		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 10703	Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services
----------------------------	--



	Program (SIAPS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	10703		
Mechanism Name:	Systems for Improved Access to Pharmaceuticals and Services		
Prime Partner Name:	Program (SIAPS) Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 11673	Mechanism Name: DoD/USDF Umbutfo Swaziland Defence Force
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 11673			
Mechanism Name: DoD/USDF Umbutfo Swaziland Defence Force			
Prime Partner Name: U.S. Department of Defense (Defense)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details



Mechanism ID: 13144	Mechanism Name: URC-Lab
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13144		
Mechanism Name:	URC-Lab		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

Approved



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13630	Mechanism Name: PSI-CPP (Combination Prevention Program)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13630			
Mechanism Name: PSI-CPP (Combination Prevention Program)			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13645	Mechanism Name: EGPAF-EPAS (Eliminating Pediatric AIDS in Swaziland)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13645
Mechanism Name:	EGPAF-EPAS (Eliminating Pediatric AIDS in Swaziland)
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13738	Mechanism Name: EGPAF-PIHTC (Provider-initiated HIV Testing & Counseling)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13738			
Mechanism Name: EGPAF-PIHTC (Provider-initiated HIV Testing & Counseling)			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 13742	Mechanism Name: C-BLD (Capacity Building and Livelihoods Development)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0
GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 13742			
Mechanism Name: C-BLD (Capacity Building and Livelihoods Development)			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13791	Mechanism Name: PSI-CIHTC (Client-initiated HIV Testing & Counseling)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13791		
Mechanism Name:	PSI-CIHTC (Client-initiated HIV Testing & Counseling)		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,999
HTC_TST_DSD	Age/sex: 10-14 Male	560
HTC_TST_DSD	Age/sex: 15-19 Male	2,188
HTC_TST_DSD	Age/sex: 20-24 Male	3,232
HTC_TST_DSD	Age/sex: 25-49 Male	13,501
HTC_TST_DSD	Age/sex: 50+ Male	55
HTC_TST_DSD	Age/sex: 10-14 Female	254
HTC_TST_DSD	Age/sex: 15-19 Female	1,254
HTC_TST_DSD	Age/sex: 20-24 Female	990
HTC_TST_DSD	Age/sex: 25-49 Female	2,037
HTC_TST_DSD	Age/sex: 50+ Female	131
HTC_TST_DSD	Sum of Age/Sex disaggregates	24,202
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	66



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	244
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	373
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	1,532
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	19
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	129
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	109
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	259
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	5
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,057
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,980
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	554
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	4,408
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,611
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	23,388
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	24,999
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	111
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	2,155
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	36
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	496
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	62
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	797
HTC_TST_DSD	Service Delivery Point (Community): Index testing	3,749



HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	2,346
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	18,507
HTC_TST_DSD	Service Delivery Point (Community): Other	397

Implementing Mechanism Details

Mechanism ID: 14201	Mechanism Name: Reducing Infection through Support & Education (RISE)		
Funding Agency: USAID	Procurement Type: Contract		
Prime Partner Name: Mothers 2 Mothers			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
G2G: No	Managing Agency:		

Total All Funding Sources: 1,119,359	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,119,359	
Funding Source	Funding Amount
GHP-State	3,096
GHP-USAID	1,116,263

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14201			
Mechanism Name:	Reducing Infection through Support & Education (RISE)		
Prime Partner Name:	Mothers 2 Mothers		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	613,537	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	505,822	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,817
PMTCT_ART_DSD	New on ART	3,311
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,717
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,817
PMTCT_STAT_DSD	Number of new ANC and L&D clients	22,862
PMTCT_STAT_DSD	By: Known positives at entry	4,651
PMTCT_STAT_DSD	By: Number of new positives identified	2,789
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	7,440
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	32
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	347
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	716
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	48
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	494
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	978
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator:	248



	<15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	3,051
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	5,386
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	8,219
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	227
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,949
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	44
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	1,002
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	30
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	226
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	2,904
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	5,139
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	7,926
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	190
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,064
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,901
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,162
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	6,650
PMTCT_EID_DSD	By infants who received their first virologic HIV test	535



	between 2 and 12 months of age	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	7,185
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	186
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	45

Implementing Mechanism Details

Mechanism ID: 14374	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14374			
Mechanism Name: APHL			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Governance and Systems	HLAB	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14437	Mechanism Name: WHO-OHSS
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14437			
Mechanism Name: WHO-OHSS			
Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Governance and Systems	OHSS	0	0
------------------------	------	---	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14842	Mechanism Name: Public Diplomacy
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 51,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 51,000	
Funding Source	Funding Amount
GHP-State	51,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 14842			
Mechanism Name: Public Diplomacy			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Approved



Care	HBHC	51,000	0
------	------	--------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16760	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-USAID	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16760		
Mechanism Name:	Applying Science to Strengthen and Improve Systems (ASSIST)		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16812	Mechanism Name: ASLM
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
-------------------------------------	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 16812			
Mechanism Name: ASLM			
Prime Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16815	Mechanism Name: Health Finance & Governance Project (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16815		
Mechanism Name:	Health Finance & Governance Project (HFG)		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16821	Mechanism Name: Health Communication Capacity Collaborative (HC3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 1,726,894	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,726,894	
Funding Source	Funding Amount
GHP-USAID	1,726,894

Cross-Cutting Budget Attribution(s)

Gender: GBV	280,010
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	16821		
Mechanism Name:	Health Communication Capacity Collaborative (HC3)		
Prime Partner Name:	Johns Hopkins University Bloomberg School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	372,597	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,159,608	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	194,689	0



Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PrEP_NEW_DSD	Number of individuals who have received antiretroviral preexposure	329
PrEP_NEW_DSD	Female 20-24	329
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	40,535
PP_PREV_DSD	Total number of people in the target population	83,194
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	30,951
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	9,584
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	7,900
KP_PREV_DSD	Total estimated number of key population in the catchment area	12,573
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,960
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,940
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment	2,519



	area)	
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	10,054
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	6,960
HTC_TST_DSD	Age/sex: 15-19 Male	177
HTC_TST_DSD	Age/sex: 20-24 Male	451
HTC_TST_DSD	Age/sex: 25-49 Male	1,091
HTC_TST_DSD	Age/sex: 15-19 Female	542
HTC_TST_DSD	Age/sex: 20-24 Female	1,374
HTC_TST_DSD	Age/sex: 25-49 Female	3,325
HTC_TST_DSD	Sum of Age/Sex disaggregates	6,960
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	18
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	44
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	110
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	52
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	137
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	331
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,720
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,240
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	6,960
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	6,960
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	171
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	521
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	6,960
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,896



TX_CURR_DSD	Age/Sex: 15-19 Male	100
TX_CURR_DSD	Age/Sex: 15-19 Female	303
TX_CURR_DSD	Sum of age/sex disaggregates	403
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	966
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,930
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,896
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	3,896
TX_CURR_DSD	Age/Sex: 20-24 Male	253
TX_CURR_DSD	Age/Sex: 25-49 Male	611
TX_CURR_DSD	Age/Sex: 20-24 Female	769
TX_CURR_DSD	Age/Sex: 25-49 Female	1,860
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	572
TX_NEW_DSD	By Age/Sex: 15-19 Male	13
TX_NEW_DSD	By Age/Sex: 20-24 Male	36
TX_NEW_DSD	By Age/Sex: 25-49 Male	91
TX_NEW_DSD	By Age/Sex: 15-19 Female	44
TX_NEW_DSD	By Age/Sex: 20-24 Female	115
TX_NEW_DSD	By Age/Sex: 25-49 Female	273
TX_NEW_DSD	Sum of Age/Sex disaggregates	572
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	140
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	432
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	572

Implementing Mechanism Details

Mechanism ID: 17096	Mechanism Name: Together for Girls (MCH Umbrella Grant)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17096			
Mechanism Name: Together for Girls (MCH Umbrella Grant)			
Prime Partner Name: United Nations Children's Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17389	Mechanism Name: Vast Grants
Funding Agency: PC	Procurement Type: Grant
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 67,821	
--	--



Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 67,821	
Funding Source	Funding Amount
GHP-State	67,821

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17389			
Mechanism Name: Vast Grants			
Prime Partner Name: U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	67,821	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,400
OVC_SERV_DSD	Age/Sex: 18+ Male	136
OVC_SERV_DSD	Age/Sex: 18+ Female	263
OVC_SERV_DSD	Sum of Age/Sex disaggregates	399
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,978
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	2,023

Implementing Mechanism Details



Mechanism ID: 17454	Mechanism Name: CHAPS VMMC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Centre for HIV and AIDS Prevention Studies Swaziland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,121,835	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,121,835	
Funding Source	Funding Amount
GHP-State	2,390,427
GHP-USAID	731,408

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17454			
Mechanism Name: CHAPS VMMC			
Prime Partner Name: Centre for HIV and AIDS Prevention Studies Swaziland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	374,621	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,747,214	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	15,616
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	3,568
VMMC_CIRC_DSD	By Age: 15-19	7,491
VMMC_CIRC_DSD	By Age: 20-24	2,347
VMMC_CIRC_DSD	By Age: 25-29	1,490
VMMC_CIRC_DSD	By Age: 30-49	720
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	13,406
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	15,616
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	15,616
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,343
HTC_TST_DSD	Age/sex: 10-14 Male	2,100
HTC_TST_DSD	Age/sex: 15-19 Male	3,841
HTC_TST_DSD	Age/sex: 20-24 Male	1,259
HTC_TST_DSD	Age/sex: 25-49 Male	1,186
HTC_TST_DSD	Age/sex: 50+ Male	0
HTC_TST_DSD	Age/sex: 10-14 Female	0
HTC_TST_DSD	Age/sex: 15-19 Female	0
HTC_TST_DSD	Age/sex: 20-24 Female	0
HTC_TST_DSD	Age/sex: 25-49 Female	0
HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	8,386
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	116



HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	208
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	68
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	62
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,088
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,255
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,088
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	9,255
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	12,343
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	170
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	503
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	0
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	0
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	12,343



Implementing Mechanism Details

Mechanism ID: 17455	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 51,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 51,000	
Funding Source	Funding Amount
GHP-State	51,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17455		
Mechanism Name:	PEPFAR Small Grants Program		
Prime Partner Name:	U.S. Department of State		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	51,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17458	Mechanism Name: ICAP – Epi-Research TA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 700,000	
Applied Pipeline Amount: 100,000	
Total All Funding Sources and Applied Pipeline Amount: 800,000	
Funding Source	Funding Amount
GHP-State	700,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17458		
Mechanism Name:	ICAP – Epi-Research TA		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	700,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17460	Mechanism Name: URC - Lubombo
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 3,028,714	
Applied Pipeline Amount: 465,983	
Total All Funding Sources and Applied Pipeline Amount: 3,494,697	
Funding Source	Funding Amount
GHP-State	3,028,714

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	153,367
---------------------------	---------

Budget Code Information

Mechanism ID: 17460			
Mechanism Name: URC - Lubombo			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	31,236	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	358,578	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	301,260	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	156,375	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,028,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	152,677	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,335
PMTCT_ART_DSD	New on ART	793
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	931
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	416
PMTCT_ART_TA	New on ART	71
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	83
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,335
PMTCT_STAT_DSD	Number of new ANC and L&D clients	5,616
PMTCT_STAT_DSD	By: Known positives at entry	1,185
PMTCT_STAT_DSD	By: Number of new positives identified	638
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	1,823
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of	18



	new positives: <15	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	82
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	160
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	35
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	155
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	296
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	179
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	728
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	1,422
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	3,147
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	140
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	675
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	23
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	369
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	10
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): <15	159
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 15-19	650
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 20-24	1,314
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 25-49	3,099
PMTCT_STAT_DSD	By Age (DREAMS SNUs ONLY): 50+	113



PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	416
PMTCT_STAT_TA	Number of new ANC and L&D clients	438
PMTCT_STAT_TA	By: Known positives at entry	100
PMTCT_STAT_TA	By: Number of new positives identified	54
PMTCT_STAT_TA	Sum of Positives Status disaggregates	154
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	3
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	13
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	25
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	1
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	7
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	13
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	9
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	53
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	113
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	250
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	13
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	58
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	2
PMTCT_STAT_TA	Required only for DREAMS countries - By new	32



	positives: 25-49	
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	13
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	51
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	100
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	243
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	9
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	39,302
HTC_TST_DSD	Age/sex: 10-14 Male	226
HTC_TST_DSD	Age/sex: 15-19 Male	2,358
HTC_TST_DSD	Age/sex: 20-24 Male	4,539
HTC_TST_DSD	Age/sex: 25-49 Male	9,154
HTC_TST_DSD	Age/sex: 50+ Male	2,022
HTC_TST_DSD	Age/sex: 10-14 Female	235
HTC_TST_DSD	Age/sex: 15-19 Female	2,352
HTC_TST_DSD	Age/sex: 20-24 Female	4,536
HTC_TST_DSD	Age/sex: 25-49 Female	9,117
HTC_TST_DSD	Age/sex: 50+ Female	2,018
HTC_TST_DSD	Sum of Age/Sex disaggregates	36,557
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	34
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	240
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	463
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	945
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	208
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	33
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	245
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	463
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	911
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	202



HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,550
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	18,084
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,558
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	18,110
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	3,108
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	36,194
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	39,302
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	158
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,859
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	170
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,818
HTC_TST_DSD	Test Result by Age: Positive: <1	74
HTC_TST_DSD	Test Result by Age: Positive: 1-9	187
HTC_TST_DSD	Age/sex: <1	775
HTC_TST_DSD	Age/sex: 1-9	1,970
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	1,097
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	29,754
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	1,719
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	105
HTC_TST_DSD	Service Delivery Point (Facility): VCT	2,312
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	0
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	3,880
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	376
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	59



HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,825
HTC_TST_TA	Age/sex: 10-14 Male	21
HTC_TST_TA	Age/sex: 15-19 Male	224
HTC_TST_TA	Age/sex: 20-24 Male	462
HTC_TST_TA	Age/sex: 25-49 Male	932
HTC_TST_TA	Age/sex: 50+ Male	216
HTC_TST_TA	Age/sex: 10-14 Female	20
HTC_TST_TA	Age/sex: 15-19 Female	221
HTC_TST_TA	Age/sex: 20-24 Female	425
HTC_TST_TA	Age/sex: 25-49 Female	860
HTC_TST_TA	Age/sex: 50+ Female	188
HTC_TST_TA	Sum of Age/Sex disaggregates	3,569
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	1
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	21
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	51
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	97
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	26
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	1
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	21
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	42
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	85
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	19
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	145
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,835
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	153
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,692
HTC_TST_TA	Sum of Aggregated Age/Sex <15	298



HTC_TST_TA	Sum of Aggregated Age/Sex 15+	3,527
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	3,825
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	11
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	196
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	17
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	166
HTC_TST_TA	Test Result by Age: Positive: <1	7
HTC_TST_TA	Test Result by Age: Positive: 1-9	19
HTC_TST_TA	Age/sex: <1	72
HTC_TST_TA	Age/sex: 1-9	184
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	0
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	3,001
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	167
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	10
HTC_TST_TA	Service Delivery Point (Facility): VCT	225
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	383
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	39
HTC_TST_TA	Service Delivery Point (Facility): Index testing	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	949
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	949
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	398



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	55
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	445
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	28
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	28
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	13
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	11
GEND_GBV_DSD	Number of people receiving post-GBV care	473
GEND_GBV_DSD	Age/Sex: <10 Male	20
GEND_GBV_DSD	Age/Sex: 10-14 Male	28
GEND_GBV_DSD	Age/Sex: 20-24 Male	27
GEND_GBV_DSD	Age/Sex: 25-49 Male	129
GEND_GBV_DSD	Age/Sex: 50+ Male	20
GEND_GBV_DSD	Age/Sex: <10 Female	20
GEND_GBV_DSD	Age/Sex: 10-14 Female	28
GEND_GBV_DSD	Age/Sex: 20-24 Female	27
GEND_GBV_DSD	Age/Sex: 25-49 Female	92
GEND_GBV_DSD	Age/Sex: 50+ Female	26



GEND_GBV_DSD	Sum of Age/Sex Disaggregates	96
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	152
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	321
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	71
GEND_GBV_DSD	Age/Sex: 15-19 Female	28
GEND_GBV_DSD	Age/Sex: 15-19 male	28
GEND_GBV_TA	Number of people receiving post-GBV care	97
GEND_GBV_TA	Age/Sex: <10 Male	4
GEND_GBV_TA	Age/Sex: 10-14 Male	6
GEND_GBV_TA	Age/Sex: 20-24 Male	5
GEND_GBV_TA	Age/Sex: 25-49 Male	25
GEND_GBV_TA	Age/Sex: 50+ Male	4
GEND_GBV_TA	Age/Sex: <10 Female	4
GEND_GBV_TA	Age/Sex: 10-14 Female	6
GEND_GBV_TA	Age/Sex: 20-24 Female	6
GEND_GBV_TA	Age/Sex: 25-49 Female	20
GEND_GBV_TA	Age/Sex: 50+ Female	5
GEND_GBV_TA	Sum of Age/Sex Disaggregates	20
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	32
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	65
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	14
GEND_GBV_TA	Age/Sex: 15-19 Female	6
GEND_GBV_TA	Age/Sex: 15-19 Male	6
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	659
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	667



TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	37
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	276
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	38
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	308
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	19
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	20
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The	9



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	36,702
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	1,388
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	15,860
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,563
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	17,891
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,832
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	1,780
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	1,692
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	90
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	568
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	21
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	246
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	24
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	277
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	28
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	27
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	27
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other	1



	(Not Xpert)	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	1,550
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	173
PMTCT_EID_DSD	Sum of Infant Age disaggregates	1,723
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	29
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	0
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	138
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	16
PMTCT_EID_TA	Sum of Infant Age disaggregates	154
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	36,636
TX_CURR_DSD	Age/Sex: 15-19 Male	96
TX_CURR_DSD	Age/Sex: 15-19 Female	1,388
TX_CURR_DSD	Sum of age/sex disaggregates	1,484
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,309
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	11,121
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,645
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	22,561
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,954
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	33,682
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	36,636
TX_CURR_DSD	Age/Sex: <1	1,279
TX_CURR_DSD	Age/Sex: <1-9	848



TX_CURR_DSD	Age/Sex: 10-14 Male	461
TX_CURR_DSD	Age/Sex: 10-14 Female	325
TX_CURR_DSD	Age/Sex: 20-24 Male	596
TX_CURR_DSD	Age/Sex: 25-49 Male	8,860
TX_CURR_DSD	Age/Sex: 50+ Male	1,581
TX_CURR_DSD	Age/Sex: 20-24 Female	4,761
TX_CURR_DSD	Age/Sex: 25-49 Female	14,620
TX_CURR_DSD	Age/Sex: 50+ Female	1,821
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	634
TX_CURR_TA	Age/Sex: 15-19 Male	0
TX_CURR_TA	Age/Sex: 15-19 Female	24
TX_CURR_TA	Sum of Age/Sex disaggregations	24
TX_CURR_TA	Aggregated Age/Sex: <15 Male	27
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	189
TX_CURR_TA	Aggregated Age/Sex: <15 Female	31
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	387
TX_CURR_TA	Sum of Aggregated Age/Sex <15	58
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	576
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	634
TX_CURR_TA	Age/Sex: <1	21
TX_CURR_TA	Age/Sex: 1-9	14
TX_CURR_TA	Age/Sex: 10-14 Male	7
TX_CURR_TA	Age/Sex: 10-14 Female	6
TX_CURR_TA	Age/Sex: 20-24 Male	9
TX_CURR_TA	Age/Sex: 25-49 Male	156
TX_CURR_TA	Age/Sex: 50+ Male	28
TX_CURR_TA	Age/Sex: 20-24 Female	81
TX_CURR_TA	Age/Sex: 25-49 Female	257
TX_CURR_TA	Age/Sex: 50+ Female	31
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,956



TX_NEW_DSD	By Age/Sex: <1	243
TX_NEW_DSD	By Age/Sex: 1-9	163
TX_NEW_DSD	By Age/Sex: 10-14 Male	89
TX_NEW_DSD	By Age/Sex: 15-19 Male	20
TX_NEW_DSD	By Age/Sex: 20-24 Male	115
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,644
TX_NEW_DSD	By Age/Sex: 50+ Male	317
TX_NEW_DSD	By Age/Sex: 10-14 Female	62
TX_NEW_DSD	By Age/Sex: 15-19 Female	267
TX_NEW_DSD	By Age/Sex: 20-24 Female	894
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,791
TX_NEW_DSD	By Age/Sex: 50+ Female	351
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,550
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	251
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,104
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	313
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,288
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,956
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	423
TX_NEW_TA	By Age/Sex: 1-9	10
TX_NEW_TA	By Age/Sex: 10-14 Male	4
TX_NEW_TA	By Age/Sex: 15-19 Male	0
TX_NEW_TA	By Age/Sex: 20-24 Male	6
TX_NEW_TA	By Age/Sex: 25-49 Male	98
TX_NEW_TA	By Age/Sex: 50+ Male	26
TX_NEW_TA	By Age/Sex: 10-14 Female	4
TX_NEW_TA	By Age/Sex: 15-19 Female	14
TX_NEW_TA	By Age/Sex: 20-24 Female	51
TX_NEW_TA	By Age/Sex: 25-49 Female	162
TX_NEW_TA	By Age/Sex: 50+ Female	33
TX_NEW_TA	Sum of Age/Sex disaggregates	398



TX_NEW_TA	Aggregated Grouping by Age: <1	15
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	19
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	127
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	23
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	254
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	423
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	24,342
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	33,343
TX_PVLS_DSD	Numerator: Indication: Routine	17,040
TX_PVLS_DSD	Numerator: Indication: Targeted	7,302
TX_PVLS_DSD	Denominator: Indication: Routine	23,338
TX_PVLS_DSD	Denominator: Indication: Targeted	10,005
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	716
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	7,754
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	880
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	14,992
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	978
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	10,615
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,204
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	20,546
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	310
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	426
TX_PVLS_TA	Numerator: Indication: Routine	218



TX_PVLS_TA	Numerator: Indication: Targeted	92
TX_PVLS_TA	Denominator: Indication: Routine	297
TX_PVLS_TA	Denominator: Indication: Targeted	129
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	10
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	98
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	12
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	190
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	12
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	134
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	16
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	264
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,307
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,767
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	184
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	105
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	65
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	85
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,281



	months after initiating ART	
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	229
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	43
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	198
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	688
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,155
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	263
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	198
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	116
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	78
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of	12



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	94
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,389
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	248
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	58
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	220
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	747
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months	2,320



	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	287
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	498
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,993
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	562
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,254
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	543
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,168
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	611



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,445
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	46
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	51
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3



TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	0



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	3



	and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	23

Implementing Mechanism Details

Mechanism ID: 17461	Mechanism Name: ICAP Lab
----------------------------	---------------------------------



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 1,754,921	
Applied Pipeline Amount: 362,010	
Total All Funding Sources and Applied Pipeline Amount: 2,116,931	
Funding Source	Funding Amount
GHP-State	1,754,921

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17461		
Mechanism Name:	ICAP Lab		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,754,921	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	57



LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	57
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	51
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	57
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	57
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	51
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	15
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	15
LAB_PT_DSD	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	14
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	15
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of	15



	laboratories that participate in this PT program	
LAB_PT_DSD	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	14
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	1
LAB_PT_DSD	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	16
LAB_PT_TA	CD4: Number of laboratories that participate in this PT program	18
LAB_PT_TA	CD4: Number of laboratories that perform this testing	34
LAB_PT_TA	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that participate in this PT program	0
LAB_PT_TA	Early infant diagnostics: Number of laboratories that perform this testing	0
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	66
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	73
LAB_PT_TA	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	93
LAB_PT_TA	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1
LAB_PT_TA	HIV viral load: Number of laboratories that participate in	1



	this PT program	
LAB_PT_TA	HIV viral load: Number of laboratories that perform this testing	1
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	11
LAB_PT_TA	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	11
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program	9
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program	11
LAB_PT_TA	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	11
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program	0
LAB_PT_TA	TB diagnostics (Culture/DST): Number of laboratories that perform this testing	0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	21
HRH_PRE	By Graduates: Laboratory professionals	21
HRH_PRE	Sum of Graduates disaggreagtes	21
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	0
INVS_COMD	Number of HIV Test Kits purchased	0



INVS_COMD	Number of HIV CD4 Reagents purchased	0
INVS_COMD	Number of Condoms purchased	0
INVS_COMD	Number of HIV Viral Load Reagents purchased	0
INVS_COMD	Number of HIV ARVs purchased	0
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	0

Implementing Mechanism Details

Mechanism ID: 17462	Mechanism Name: Strengthening MOH Leadership, Governance & Quality Management
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Swaziland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 153,055	
Applied Pipeline Amount: 346,945	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	153,055

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17462



Mechanism Name:	Strengthening MOH Leadership, Governance & Quality Management		
Prime Partner Name:	Ministry of Health and Social Welfare, Swaziland		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,308	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	150,747	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17463	Mechanism Name: ICAP-Manzini
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,760,862	
Applied Pipeline Amount: 652,339	
Total All Funding Sources and Applied Pipeline Amount: 5,413,201	
Funding Source	Funding Amount
GHP-State	4,760,862

Cross-Cutting Budget Attribution(s)

Motor Vehicles: Purchased	299,651
---------------------------	---------



Budget Code Information

Mechanism ID:	17463		
Mechanism Name:	ICAP-Manzini		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	212,954	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,080,289	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	66,594	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	258,180	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,882,723	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	260,122	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,496
PMTCT_ART_DSD	New on ART	1,891



PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,394
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	36
PMTCT_ART_TA	New on ART	33
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	16
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	9,496
PMTCT_STAT_DSD	Number of new ANC and L&D clients	9,952
PMTCT_STAT_DSD	By: Known positives at entry	2,235
PMTCT_STAT_DSD	By: Number of new positives identified	1,238
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	3,473
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	13
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	235
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	413
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	18
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	426
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	734
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	98
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	1,893
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	3,285
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 25-49	4,576
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator:	100



	50+	
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	1,036
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	19
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	566
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	13
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	94
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	1,805
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	3,137
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	4,365
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	95
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	36
PMTCT_STAT_TA	Number of new ANC and L&D clients	75
PMTCT_STAT_TA	By: Known positives at entry	25
PMTCT_STAT_TA	By: Number of new positives identified	11
PMTCT_STAT_TA	Sum of Positives Status disaggregates	36
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	5
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	8
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	2
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	4



PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	1
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	14
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	25
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	34
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	1
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	12
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	5
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	0
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	7
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	12
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	17
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,998
HTC_TST_DSD	Age/sex: 10-14 Male	741
HTC_TST_DSD	Age/sex: 15-19 Male	570
HTC_TST_DSD	Age/sex: 20-24 Male	1,707
HTC_TST_DSD	Age/sex: 25-49 Male	5,118
HTC_TST_DSD	Age/sex: 50+ Male	1,028
HTC_TST_DSD	Age/sex: 10-14 Female	331
HTC_TST_DSD	Age/sex: 15-19 Female	1,265



HTC_TST_DSD	Age/sex: 20-24 Female	2,752
HTC_TST_DSD	Age/sex: 25-49 Female	5,114
HTC_TST_DSD	Age/sex: 50+ Female	1,503
HTC_TST_DSD	Sum of Age/Sex disaggregates	20,129
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	64
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	408
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	26
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	10
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	74
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	235
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	729
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	73
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,626
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	8,425
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,313
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	10,634
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	4,939
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	19,059
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	23,998
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	36
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	514
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	30
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	1,101



HTC_TST_DSD	Test Result by Age: Positive: <1	13
HTC_TST_DSD	Test Result by Age: Positive: 1-9	33
HTC_TST_DSD	Age/sex: <1	1,481
HTC_TST_DSD	Age/sex: 1-9	2,388
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	925
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	8,086
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	3,274
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	45
HTC_TST_DSD	Service Delivery Point (Facility): VCT	4,184
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	7,140
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	260
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	84
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	352
HTC_TST_TA	Age/sex: 10-14 Male	0
HTC_TST_TA	Age/sex: 15-19 Male	5
HTC_TST_TA	Age/sex: 20-24 Male	36
HTC_TST_TA	Age/sex: 25-49 Male	115
HTC_TST_TA	Age/sex: 50+ Male	23
HTC_TST_TA	Age/sex: 10-14 Female	0
HTC_TST_TA	Age/sex: 15-19 Female	14
HTC_TST_TA	Age/sex: 20-24 Female	34
HTC_TST_TA	Age/sex: 25-49 Female	76
HTC_TST_TA	Age/sex: 50+ Female	10
HTC_TST_TA	Sum of Age/Sex disaggregates	313
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	1
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	10
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	0



HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	3
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	12
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	27
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	179
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	134
HTC_TST_TA	Sum of Aggregated Age/Sex <15	39
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	313
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	352
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	11
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	15
HTC_TST_TA	Test Result by Age: Positive: <1	0
HTC_TST_TA	Test Result by Age: Positive: 1-9	0
HTC_TST_TA	Age/sex: <1	17
HTC_TST_TA	Age/sex: 1-9	22
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	14
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	119
HTC_TST_TA	Service Delivery Point (Facility): Pediatric	38
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	22
HTC_TST_TA	Service Delivery Point (Facility): VCT	61
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	79



HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	8
HTC_TST_TA	Service Delivery Point (Facility): Index testing	11
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,132
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,266
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	52
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,021
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	54
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,005
GEND_GBV_DSD	Number of people receiving post-GBV care	211
GEND_GBV_DSD	Age/Sex: <10 Male	0
GEND_GBV_DSD	Age/Sex: 10-14 Male	0
GEND_GBV_DSD	Age/Sex: 20-24 Male	15
GEND_GBV_DSD	Age/Sex: 25-49 Male	23
GEND_GBV_DSD	Age/Sex: 50+ Male	0
GEND_GBV_DSD	Age/Sex: <10 Female	10
GEND_GBV_DSD	Age/Sex: 10-14 Female	17
GEND_GBV_DSD	Age/Sex: 20-24 Female	45
GEND_GBV_DSD	Age/Sex: 25-49 Female	55
GEND_GBV_DSD	Age/Sex: 50+ Female	9
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	27
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	169
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	42



GEND_GBVDSD	By PEP service provision (related to sexual violence services provided)	42
GEND_GBVDSD	Age/Sex: 15-19 Female	27
GEND_GBVDSD	Age/Sex: 15-19 male	10
GEND_GBVTa	Number of people receiving post-GBV care	2
GEND_GBVTa	Age/Sex: <10 Male	0
GEND_GBVTa	Age/Sex: 10-14 Male	0
GEND_GBVTa	Age/Sex: 20-24 Male	0
GEND_GBVTa	Age/Sex: 25-49 Male	1
GEND_GBVTa	Age/Sex: 50+ Male	0
GEND_GBVTa	Age/Sex: <10 Female	0
GEND_GBVTa	Age/Sex: 10-14 Female	0
GEND_GBVTa	Age/Sex: 20-24 Female	0
GEND_GBVTa	Age/Sex: 25-49 Female	1
GEND_GBVTa	Age/Sex: 50+ Female	0
GEND_GBVTa	Sum of Age/Sex Disaggregates	0
GEND_GBVTa	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2
GEND_GBVTa	By type of service: Sexual Violence (Post-Rape Care)	0
GEND_GBVTa	By PEP service provision (related to sexual violence services provided)	0
GEND_GBVTa	Age/Sex: 15-19 Female	0
GEND_GBVTa	Age/Sex: 15-19 Male	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,449
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,738
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	22

TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	737
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	682
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	37,821
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	797
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	11,610
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	1,620
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	23,794
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	1,133
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	150
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	150
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	143
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	0
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	30
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	1



TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	112
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	5
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,163
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	122
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,285
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	109
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	19
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	47
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	2
PMTCT_EID_TA	Sum of Infant Age disaggregates	49
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	3
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	46,350
TX_CURR_DSD	Age/Sex: 15-19 Male	387
TX_CURR_DSD	Age/Sex: 15-19 Female	800
TX_CURR_DSD	Sum of age/sex disaggregates	1,187
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,250



TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,484
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,631
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	29,985
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,881
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	43,469
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	46,350
TX_CURR_DSD	Age/Sex: <1	93
TX_CURR_DSD	Age/Sex: <1-9	1,721
TX_CURR_DSD	Age/Sex: 10-14 Male	530
TX_CURR_DSD	Age/Sex: 10-14 Female	537
TX_CURR_DSD	Age/Sex: 20-24 Male	257
TX_CURR_DSD	Age/Sex: 25-49 Male	9,890
TX_CURR_DSD	Age/Sex: 50+ Male	2,950
TX_CURR_DSD	Age/Sex: 20-24 Female	2,282
TX_CURR_DSD	Age/Sex: 25-49 Female	22,775
TX_CURR_DSD	Age/Sex: 50+ Female	4,128
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	215
TX_CURR_TA	Age/Sex: 15-19 Male	1
TX_CURR_TA	Age/Sex: 15-19 Female	1
TX_CURR_TA	Sum of Age/Sex disaggregations	2
TX_CURR_TA	Aggregated Age/Sex: <15 Male	0
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	30
TX_CURR_TA	Aggregated Age/Sex: <15 Female	2
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	183
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	213
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	215
TX_CURR_TA	Age/Sex: <1	1
TX_CURR_TA	Age/Sex: 1-9	0
TX_CURR_TA	Age/Sex: 10-14 Male	0
TX_CURR_TA	Age/Sex: 10-14 Female	1



TX_CURR_TA	Age/Sex: 20-24 Male	2
TX_CURR_TA	Age/Sex: 25-49 Male	22
TX_CURR_TA	Age/Sex: 50+ Male	6
TX_CURR_TA	Age/Sex: 20-24 Female	26
TX_CURR_TA	Age/Sex: 25-49 Female	82
TX_CURR_TA	Age/Sex: 50+ Female	73
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,843
TX_NEW_DSD	By Age/Sex: <1	104
TX_NEW_DSD	By Age/Sex: 1-9	190
TX_NEW_DSD	By Age/Sex: 10-14 Male	50
TX_NEW_DSD	By Age/Sex: 15-19 Male	32
TX_NEW_DSD	By Age/Sex: 20-24 Male	90
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,479
TX_NEW_DSD	By Age/Sex: 50+ Male	218
TX_NEW_DSD	By Age/Sex: 10-14 Female	71
TX_NEW_DSD	By Age/Sex: 15-19 Female	331
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,098
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,911
TX_NEW_DSD	By Age/Sex: 50+ Female	269
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,549
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	185
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,819
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	205
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,634
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,843
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	83
TX_NEW_TA	By Age/Sex: 1-9	0
TX_NEW_TA	By Age/Sex: 10-14 Male	0
TX_NEW_TA	By Age/Sex: 15-19 Male	0
TX_NEW_TA	By Age/Sex: 20-24 Male	0



TX_NEW_TA	By Age/Sex: 25-49 Male	10
TX_NEW_TA	By Age/Sex: 50+ Male	1
TX_NEW_TA	By Age/Sex: 10-14 Female	0
TX_NEW_TA	By Age/Sex: 15-19 Female	10
TX_NEW_TA	By Age/Sex: 20-24 Female	24
TX_NEW_TA	By Age/Sex: 25-49 Female	37
TX_NEW_TA	By Age/Sex: 50+ Female	0
TX_NEW_TA	Sum of Age/Sex disaggregates	82
TX_NEW_TA	Aggregated Grouping by Age: <1	1
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	11
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	71
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	83
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	26,460
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	36,247
TX_PVLS_DSD	Numerator: Indication: Routine	23,812
TX_PVLS_DSD	Numerator: Indication: Targeted	2,649
TX_PVLS_DSD	Denominator: Indication: Routine	32,620
TX_PVLS_DSD	Denominator: Indication: Targeted	3,627
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,321
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	11,910
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	1,321
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	11,908
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,813
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	16,310
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	1,813



TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	16,311
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	35
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	47
TX_PVLS_TA	Numerator: Indication: Routine	31
TX_PVLS_TA	Numerator: Indication: Targeted	4
TX_PVLS_TA	Denominator: Indication: Routine	42
TX_PVLS_TA	Denominator: Indication: Targeted	5
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	2
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	15
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	2
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	16
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	2
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	22
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	2
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	21
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,185
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	7,894
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	109
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	195
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12	53



	months after initiating ART	
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	33
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,563
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	228
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	47
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	284
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,094
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,199
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	287
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	118
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	213



	beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	54
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	36
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	129
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,706
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	247
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including	311



	those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,204
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,516
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	310
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	192
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,917
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	211
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,865
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	206
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	2,111



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	230
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,347
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	87
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	96
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	0



	and those lost to follow-up)	
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28



TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	75
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	83

Implementing Mechanism Details

Mechanism ID: 17464	Mechanism Name: Rapid and Effective Action for Combating HIV/AIDS III (REACH 3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 4,728,202	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,728,202	
Funding Source	Funding Amount
GHP-State	4,728,202

Cross-Cutting Budget Attribution(s)

Gender: GBV	280,010
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Capacity building
-----------	-------------------

Budget Code Information

Mechanism ID: 17464			
Mechanism Name: Rapid and Effective Action for Combating HIV/AIDS III (REACH 3)			
Prime Partner Name: Pact			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	808,070	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,131,779	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	379,907	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	408,446	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	39,879
PP_PREV_DSD	Total number of people in the target population	86,043
PP_PREV_DSD	Aggregated Age/sex: <15 Female	14,967
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	24,912
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	45,874



	HIV/AIDS	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	3,516
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	4,581
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	2,641
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	2,453
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	2,331
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	3,403
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,569
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	1,779
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	1,482
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	1,278
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	398
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	327
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	2,298



	and sex: Economic Strengthening Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	3,027
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,134
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	1,173
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	4,025
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	4,541
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,924
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	1,994
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	16,149
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	29,725

Implementing Mechanism Details

Mechanism ID: 17465	Mechanism Name: AIDSFree
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 6,408,846	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,408,846	
Funding Source	Funding Amount
GHP-State	6,408,846

Cross-Cutting Budget Attribution(s)



Motor Vehicles: Purchased	445,935
---------------------------	---------

Budget Code Information

Mechanism ID: 17465			
Mechanism Name: AIDSFree			
Prime Partner Name: John Snow, Inc.			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	65,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	367,284	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	854,822	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	382,981	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,317,628	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	421,131	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	13,078



	their results)	
PMTCT_ART_DSD	New on ART	1,493
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,547
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	420
PMTCT_ART_TA	New on ART	50
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	84
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	13,078
PMTCT_STAT_DSD	Number of new ANC and L&D clients	13,768
PMTCT_STAT_DSD	By: Known positives at entry	2,745
PMTCT_STAT_DSD	By: Number of new positives identified	1,598
PMTCT_STAT_DSD	Sum of Positives Status disaggregates	4,343
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: <15	5
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 15-19	75
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 20-24	239
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: <15	10
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 15-19	31
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 20-24	191
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15	72
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: <15-19	969
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 20-24	1,669
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator:	2,252



	25-49	
PMTCT_STAT_DSD	Required only for DREAMS Countries - Denominator: 50+	50
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 25-49	752
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of known positives: 50+	15
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 25-49	251
PMTCT_STAT_DSD	Required only for DREAMS Countries - By Number of new positives: 50+	12
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): <15	47
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 15-19	905
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 20-24	1,572
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 25-49	2,193
PMTCT_STAT_DSD	By Age (DREAMS SNU's ONLY): 50+	46
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	420
PMTCT_STAT_TA	Number of new ANC and L&D clients	442
PMTCT_STAT_TA	By: Known positives at entry	88
PMTCT_STAT_TA	By: Number of new positives identified	51
PMTCT_STAT_TA	Sum of Positives Status disaggregates	139
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 15-19	2
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 20-24	12
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: <15	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 15-19	5



PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 20-24	14
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: <15	3
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 15-19	54
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 20-24	99
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 25-49	143
PMTCT_STAT_TA	Required only for DREAMS countries - Denominator: 50+	3
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 25-49	46
PMTCT_STAT_TA	Required only for DREAMS countries - By known positives: 50+	0
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 25-49	15
PMTCT_STAT_TA	Required only for DREAMS countries - By new positives: 50+	1
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): <15	2
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 15-19	54
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 20-24	95
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 25-49	133
PMTCT_STAT_TA	By Age (DREAMS SNU's ONLY): 50+	3
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	70,280
HTC_TST_DSD	Age/sex: 10-14 Male	131
HTC_TST_DSD	Age/sex: 15-19 Male	633
HTC_TST_DSD	Age/sex: 20-24 Male	1,993
HTC_TST_DSD	Age/sex: 25-49 Male	6,380
HTC_TST_DSD	Age/sex: 50+ Male	1,097



HTC_TST_DSD	Age/sex: 10-14 Female	132
HTC_TST_DSD	Age/sex: 15-19 Female	1,428
HTC_TST_DSD	Age/sex: 20-24 Female	3,422
HTC_TST_DSD	Age/sex: 25-49 Female	6,754
HTC_TST_DSD	Age/sex: 50+ Female	967
HTC_TST_DSD	Sum of Age/Sex disaggregates	22,937
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	4
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	24
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	89
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	691
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	60
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	14
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	100
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	408
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	972
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	53
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	11,478
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	23,560
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,017
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	31,224
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	15,495
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	54,784
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	70,279
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	169
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	1,954
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	162



HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	4,024
HTC_TST_DSD	Test Result by Age: Positive: <1	32
HTC_TST_DSD	Test Result by Age: Positive: 1-9	55
HTC_TST_DSD	Age/sex: <1	2,170
HTC_TST_DSD	Age/sex: 1-9	2,744
HTC_TST_DSD	Service Delivery Point (Facility): Inpatient	643
HTC_TST_DSD	Service Delivery Point (Facility): Outpatient	22,304
HTC_TST_DSD	Service Delivery Point (Facility): Pediatric	10,385
HTC_TST_DSD	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_DSD	Service Delivery Point (Facility): Other PITC	9,880
HTC_TST_DSD	Service Delivery Point (Facility): VCT	9,555
HTC_TST_DSD	Service Delivery Point (Facility): VMMC	40
HTC_TST_DSD	Service Delivery Point (Facility): PMTCT	13,186
HTC_TST_DSD	Service Delivery Point (Facility): TB Clinics	772
HTC_TST_DSD	Service Delivery Point (Facility): Index testing	3,514
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,296
HTC_TST_TA	Age/sex: 10-14 Male	4
HTC_TST_TA	Age/sex: 15-19 Male	0
HTC_TST_TA	Age/sex: 20-24 Male	71
HTC_TST_TA	Age/sex: 25-49 Male	311
HTC_TST_TA	Age/sex: 50+ Male	34
HTC_TST_TA	Age/sex: 10-14 Female	0
HTC_TST_TA	Age/sex: 15-19 Female	34
HTC_TST_TA	Age/sex: 20-24 Female	134
HTC_TST_TA	Age/sex: 25-49 Female	232
HTC_TST_TA	Age/sex: 50+ Female	9
HTC_TST_TA	Sum of Age/Sex disaggregates	829
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Male	0



HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Male	11
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Male	37
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Male	4
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Female	0
HTC_TST_TA	Test Result by Age and Sex: Positive: 15-19 Female	4
HTC_TST_TA	Test Result by Age and Sex: Positive: 20-24 Female	19
HTC_TST_TA	Test Result by Age and Sex: Positive: 25-49 Female	50
HTC_TST_TA	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	425
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	868
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	161
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	842
HTC_TST_TA	Sum of Aggregated Age/Sex <15	586
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	1,710
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	2,296
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Male	94
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive <15 Female	2
HTC_TST_TA	Test Result by Aggregated Age and Sex: Positive 15+ Female	128
HTC_TST_TA	Test Result by Age: Positive: <1	0
HTC_TST_TA	Test Result by Age: Positive: 1-9	0
HTC_TST_TA	Age/sex: <1	209
HTC_TST_TA	Age/sex: 1-9	214
HTC_TST_TA	Service Delivery Point (Facility): Inpatient	0
HTC_TST_TA	Service Delivery Point (Facility): Outpatient	665



HTC_TST_TA	Service Delivery Point (Facility): Pediatric	453
HTC_TST_TA	Service Delivery Point (Facility): Malnutrition facilities	0
HTC_TST_TA	Service Delivery Point (Facility): Other PITC	180
HTC_TST_TA	Service Delivery Point (Facility): VCT	352
HTC_TST_TA	Service Delivery Point (Facility): VMMC	0
HTC_TST_TA	Service Delivery Point (Facility): PMTCT	529
HTC_TST_TA	Service Delivery Point (Facility): TB Clinics	0
HTC_TST_TA	Service Delivery Point (Facility): Index testing	117
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,518
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,624
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,309
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	87
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,046
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	31
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	32
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31



TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
GEND_GBV_DSD	Number of people receiving post-GBV care	963
GEND_GBV_DSD	Age/Sex: <10 Male	13
GEND_GBV_DSD	Age/Sex: 10-14 Male	20
GEND_GBV_DSD	Age/Sex: 20-24 Male	15
GEND_GBV_DSD	Age/Sex: 25-49 Male	12
GEND_GBV_DSD	Age/Sex: 50+ Male	6
GEND_GBV_DSD	Age/Sex: <10 Female	138
GEND_GBV_DSD	Age/Sex: 10-14 Female	140
GEND_GBV_DSD	Age/Sex: 20-24 Female	131
GEND_GBV_DSD	Age/Sex: 25-49 Female	257
GEND_GBV_DSD	Age/Sex: 50+ Female	83
GEND_GBV_DSD	Sum of Age/Sex Disaggregates	311
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	721
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	242
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	218
GEND_GBV_DSD	Age/Sex: 15-19 Female	133
GEND_GBV_DSD	Age/Sex: 15-19 male	15
GEND_GBV_TA	Number of people receiving post-GBV care	128
GEND_GBV_TA	Age/Sex: <10 Male	2
GEND_GBV_TA	Age/Sex: 10-14 Male	3
GEND_GBV_TA	Age/Sex: 20-24 Male	2
GEND_GBV_TA	Age/Sex: 25-49 Male	1
GEND_GBV_TA	Age/Sex: 50+ Male	1
GEND_GBV_TA	Age/Sex: <10 Female	20
GEND_GBV_TA	Age/Sex: 10-14 Female	20



GEND_GBV_TA	Age/Sex: 20-24 Female	17
GEND_GBV_TA	Age/Sex: 25-49 Female	33
GEND_GBV_TA	Age/Sex: 50+ Female	8
GEND_GBV_TA	Sum of Age/Sex Disaggregates	45
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	96
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	32
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	30
GEND_GBV_TA	Age/Sex: 15-19 Female	18
GEND_GBV_TA	Age/Sex: 15-19 Male	3
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,804
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,007
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	60
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	926
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	746
TB_ART_TA	The number of registered new and relapse TB cases	17



	with documented HIV-positive status who are on ART during TB treatment during the reporting period	
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	19
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_SCREENDX_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	66,928
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Male	2,585
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Male	21,064
TB_SCREENDX_DSD	Screened for TB by Age/Sex:<15 Female	2,440
TB_SCREENDX_DSD	Screened for TB by Age/Sex: 15+ Female	40,838
TB_SCREENDX_DSD	Screen Result: Screened Positive for TB	6,690
TB_SCREENDX_DSD	[Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	6,357
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only	0
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert	6,356



	MTB/RIF assay	
TB_SCREENDX_DSD	[Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert)	0
TB_SCREENDX_TA	The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period.	794
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Male	10
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Male	425
TB_SCREENDX_TA	Screened for TB by Age/Sex: <15 Female	9
TB_SCREENDX_TA	Screened for TB by Age/Sex: 15+ Female	341
TB_SCREENDX_TA	Screen Results: Screened Positive for TB	79
TB_SCREENDX_TA	[Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB	73
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only	0
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay	73
TB_SCREENDX_TA	[Sub-disagg of Specimen Sent] Diagnostic Test: Other (Not Xpert)	0
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,794
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	419
PMTCT_EID_DSD	Sum of Infant Age disaggregates	4,213
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	117
PMTCT_EID_DSD	Number of infants with a positive virological test result within 12 months of birth	43
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth	120
PMTCT_EID_TA	By infants who received their first virologic HIV test between 2 and 12 months of age	15
PMTCT_EID_TA	Sum of Infant Age disaggregates	135
PMTCT_EID_TA	Number of infants with a positive virological test result	4



	within 2 months of birth	
PMTCT_EID_TA	Number of infants with a positive virological test result within 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	64,600
TX_CURR_DSD	Age/Sex: 15-19 Male	118
TX_CURR_DSD	Age/Sex: 15-19 Female	714
TX_CURR_DSD	Sum of age/sex disaggregates	832
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,748
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	20,377
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,316
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	40,159
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,064
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	60,536
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	64,600
TX_CURR_DSD	Age/Sex: <1	291
TX_CURR_DSD	Age/Sex: <1-9	780
TX_CURR_DSD	Age/Sex: 10-14 Male	163
TX_CURR_DSD	Age/Sex: 10-14 Female	170
TX_CURR_DSD	Age/Sex: 20-24 Male	415
TX_CURR_DSD	Age/Sex: 25-49 Male	8,316
TX_CURR_DSD	Age/Sex: 50+ Male	1,366
TX_CURR_DSD	Age/Sex: 20-24 Female	2,991
TX_CURR_DSD	Age/Sex: 25-49 Female	13,691
TX_CURR_DSD	Age/Sex: 50+ Female	1,690
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	659
TX_CURR_TA	Age/Sex: 15-19 Male	3
TX_CURR_TA	Age/Sex: 15-19 Female	6
TX_CURR_TA	Sum of Age/Sex disaggregations	9
TX_CURR_TA	Aggregated Age/Sex: <15 Male	9
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	311



TX_CURR_TA	Aggregated Age/Sex: <15 Female	10
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	329
TX_CURR_TA	Sum of Aggregated Age/Sex <15	19
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	640
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	659
TX_CURR_TA	Age/Sex: <1	4
TX_CURR_TA	Age/Sex: 1-9	1
TX_CURR_TA	Age/Sex: 10-14 Male	0
TX_CURR_TA	Age/Sex: 10-14 Female	2
TX_CURR_TA	Age/Sex: 20-24 Male	11
TX_CURR_TA	Age/Sex: 25-49 Male	181
TX_CURR_TA	Age/Sex: 50+ Male	6
TX_CURR_TA	Age/Sex: 20-24 Female	43
TX_CURR_TA	Age/Sex: 25-49 Female	108
TX_CURR_TA	Age/Sex: 50+ Female	5
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,915
TX_NEW_DSD	By Age/Sex: <1	68
TX_NEW_DSD	By Age/Sex: 1-9	101
TX_NEW_DSD	By Age/Sex: 10-14 Male	29
TX_NEW_DSD	By Age/Sex: 15-19 Male	21
TX_NEW_DSD	By Age/Sex: 20-24 Male	65
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,320
TX_NEW_DSD	By Age/Sex: 50+ Male	188
TX_NEW_DSD	By Age/Sex: 10-14 Female	25
TX_NEW_DSD	By Age/Sex: 15-19 Female	238
TX_NEW_DSD	By Age/Sex: 20-24 Female	799
TX_NEW_DSD	By Age/Sex: 25-49 Female	2,523
TX_NEW_DSD	By Age/Sex: 50+ Female	196
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,404
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	511
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,908



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	439
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	9,847
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	14,705
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	442
TX_NEW_TA	By Age/Sex: 1-9	6
TX_NEW_TA	By Age/Sex: 10-14 Male	0
TX_NEW_TA	By Age/Sex: 15-19 Male	3
TX_NEW_TA	By Age/Sex: 20-24 Male	7
TX_NEW_TA	By Age/Sex: 25-49 Male	85
TX_NEW_TA	By Age/Sex: 50+ Male	0
TX_NEW_TA	By Age/Sex: 10-14 Female	0
TX_NEW_TA	By Age/Sex: 15-19 Female	5
TX_NEW_TA	By Age/Sex: 20-24 Female	34
TX_NEW_TA	By Age/Sex: 25-49 Female	102
TX_NEW_TA	By Age/Sex: 50+ Female	5
TX_NEW_TA	Sum of Age/Sex disaggregates	241
TX_NEW_TA	Aggregated Grouping by Age: <1	7
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	11
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	151
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	7
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	273
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	442
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	58,139
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	64,600
TX_PVLS_DSD	Numerator: Indication: Routine	49,417
TX_PVLS_DSD	Numerator: Indication: Targeted	8,722
TX_PVLS_DSD	Denominator: Indication: Routine	54,909



TX_PVLS_DSD	Denominator: Indication: Targeted	9,691
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Male	1,576
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Male	18,339
TX_PVLS_DSD	Numerator Aggregated Age/Sex: <15 Female	2,083
TX_PVLS_DSD	Numerator Aggregated Age/Sex: 15+ Female	36,141
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Male	1,749
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Male	20,380
TX_PVLS_DSD	Denominator Aggregated Age/Sex: <15 Female	2,314
TX_PVLS_DSD	Denominator Aggregated Age/Sex: 15+ Female	40,155
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	591
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	659
TX_PVLS_TA	Numerator: Indication: Routine	501
TX_PVLS_TA	Numerator: Indication: Targeted	90
TX_PVLS_TA	Denominator: Indication: Routine	560
TX_PVLS_TA	Denominator: Indication: Targeted	99
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Male	8
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Male	280
TX_PVLS_TA	Numerator Aggregated Age/Sex: <15 Female	9
TX_PVLS_TA	Numerator Aggregated Age/Sex: 15+ Female	294
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Male	9
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Male	311
TX_PVLS_TA	Denominator Aggregated Age/Sex: <15 Female	10
TX_PVLS_TA	Denominator Aggregated Age/Sex: 15+ Female	329
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	8,283
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	9,051



	stopped ART, and those lost to follow-up	
TX_RET_DSD	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	39
TX_RET_DSD	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	66
TX_RET_DSD	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	22
TX_RET_DSD	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	48
TX_RET_DSD	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	808
TX_RET_DSD	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	119
TX_RET_DSD	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	18
TX_RET_DSD	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	161
TX_RET_DSD	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	514
TX_RET_DSD	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,620
TX_RET_DSD	Age/Sex: 50+ Female (Numerator: Number of adults)	128



	and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41
TX_RET_DSD	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	71
TX_RET_DSD	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	22
TX_RET_DSD	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_DSD	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	51
TX_RET_DSD	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	885
TX_RET_DSD	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART,	131



	and those lost to follow-up)	
TX_RET_DSD	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	175
TX_RET_DSD	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	563
TX_RET_DSD	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,768
TX_RET_DSD	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	140
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	202
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,053
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	642



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,387
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	216
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,243
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	699
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,893
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	204
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	222
TX_RET_TA	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0



TX_RET_TA	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_TA	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_TA	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_TA	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_TA	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15
TX_RET_TA	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_TA	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1
TX_RET_TA	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1



TX_RET_TA	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_TA	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31
TX_RET_TA	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_TA	Age/Sex: 15-19 Female (Denominator: Total number of	2



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_TA	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42
TX_RET_TA	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	67
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	129
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	6



	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	72
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142

Implementing Mechanism Details

Mechanism ID: 17548	Mechanism Name: Supply Chain Management System (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0
GHP-USAID	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17548			
Mechanism Name: Supply Chain Management System (SCMS)			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17555	Mechanism Name: USDF MeHIN
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: VISTA PARTNERS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

Budget Code Information

Mechanism ID: 17555			
Mechanism Name: USDF MeHIN			
Prime Partner Name: VISTA PARTNERS			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17559	Mechanism Name: RPSO-Supported Renovation Projects in Swaziland MOH Facilities
Funding Agency: State/AF	Procurement Type: Contract
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17559			
Mechanism Name: RPSO-Supported Renovation Projects in Swaziland MOH Facilities			
Prime Partner Name: Regional Procurement Support Office/Frankfurt			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17572	Mechanism Name: TA Support for the Strengthening of Blood Transfusion
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Association of Blood Banks	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17572		
Mechanism Name:	TA Support for the Strengthening of Blood Transfusion		
Prime Partner Name:	American Association of Blood Banks		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17775	Mechanism Name: Building Local Capacity (BLC)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17775			
Mechanism Name: Building Local Capacity (BLC)			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17965	Mechanism Name: 4Children
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 795,742	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 795,742	
Funding Source	Funding Amount
GHP-State	795,742

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 17965			
Mechanism Name: 4Children			
Prime Partner Name: Catholic Relief Services			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	675,649	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	120,093	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,000
OVC_SERV_DSD	Age/Sex: 18+ Male	0
OVC_SERV_DSD	Age/Sex: 18+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	0
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Male	1,379
OVC_SERV_DSD	By Aggregated Age/Sex: <18 Female	1,621

Implementing Mechanism Details

Mechanism ID: 17966	Mechanism Name: Support for International Family Planning and Health Organization 2 (SIFPO 2)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 761,690	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 761,690	
Funding Source	Funding Amount
GHP-State	761,690

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17966		
Mechanism Name:	Support for International Family Planning and Health Organization 2		
Prime Partner Name:	(SIFPO 2) Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	65,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	696,690	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
PP_PREV_DSD	Number of the target population who completed a	21,102



	standardized HIV prevention intervention including the minimum components during the reporting period.	
PP_PREV_DSD	Total number of people in the target population	25,103
PP_PREV_DSD	Aggregated Age/sex: <15 Male	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Male	9,698
PP_PREV_DSD	Aggregated Age/sex: <15 Female	0
PP_PREV_DSD	Aggregated Age/sex: 15+ Female	11,404
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	21,103
HTC_TST_DSD	Age/sex: 10-14 Male	0
HTC_TST_DSD	Age/sex: 15-19 Male	0
HTC_TST_DSD	Age/sex: 20-24 Male	0
HTC_TST_DSD	Age/sex: 25-49 Male	0
HTC_TST_DSD	Age/sex: 50+ Male	0
HTC_TST_DSD	Age/sex: 10-14 Female	1,634
HTC_TST_DSD	Age/sex: 15-19 Female	8,116
HTC_TST_DSD	Age/sex: 20-24 Female	11,353
HTC_TST_DSD	Age/sex: 25-49 Female	0
HTC_TST_DSD	Age/sex: 50+ Female	0
HTC_TST_DSD	Sum of Age/Sex disaggregates	21,103
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Male	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 10-14 Female	196
HTC_TST_DSD	Test Result by Age and Sex: Positive: 15-19 Female	910
HTC_TST_DSD	Test Result by Age and Sex: Positive: 20-24 Female	1,315
HTC_TST_DSD	Test Result by Age and Sex: Positive: 25-49 Female	0
HTC_TST_DSD	Test Result by Age and Sex: Positive: 50+ Female	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION	0



	ONLY: <15 Male	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,634
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,469
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	1,634
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	19,469
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	21,103
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Male	0
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive <15 Female	196
HTC_TST_DSD	Test Result by Aggregated Age and Sex: Positive 15+ Female	2,225
HTC_TST_DSD	Test Result by Age: Positive: <1	0
HTC_TST_DSD	Test Result by Age: Positive: 1-9	0
HTC_TST_DSD	Age/sex: <1	0
HTC_TST_DSD	Age/sex: 1-9	0
HTC_TST_DSD	Service Delivery Point (Community): Index testing	0
HTC_TST_DSD	Service Delivery Point (Community): Homebased testing	0
HTC_TST_DSD	Service Delivery Point (Community): Mobile testing	21,103
HTC_TST_DSD	Service Delivery Point (Community): Other	0

Implementing Mechanism Details

Mechanism ID: 17967	TBD: Yes
REDACTED	



Implementing Mechanism Details

Mechanism ID: 17972	Mechanism Name: Measure Evaluation Phase IV
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Measure Evaluation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	Funding Amount
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17972			
Mechanism Name: Measure Evaluation Phase IV			
Prime Partner Name: Measure Evaluation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Approved



Mechanism ID: 18169	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18250	Mechanism Name: WHO/AFRO Disease Control
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: WHO/AFRO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 500,000	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 500,000	
Funding Source	Funding Amount
GHP-State	500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18250		
Mechanism Name:	WHO/AFRO Disease Control		
Prime Partner Name:	WHO/AFRO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	50,000	0
-----------	------	--------	---

Implementing Mechanism Indicator Information

Indicator Number	Label	2017
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	339
HRH_PRE	By Graduates: Doctors	0
HRH_PRE	By Graduates: Nurses	145
HRH_PRE	By Graduates: Midwives	85
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	21
HRH_PRE	By Graduates: Other	88
HRH_PRE	Sum of Graduates disaggreagtes	339

Implementing Mechanism Details

Mechanism ID: 18272	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18329	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18331	Mechanism Name: Global Health Supply Chain - Procurement and Supply Chain Management (GHSC-PSM)
---------------------	---



Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 6,166,486	
Applied Pipeline Amount: 300,000	
Total All Funding Sources and Applied Pipeline Amount: 6,466,486	
Funding Source	Funding Amount
GHP-State	6,166,486

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18331		
Mechanism Name:	Global Health Supply Chain - Procurement and Supply Chain Management (GHSC-PSM)		
Prime Partner Name:	Global Health Supply Chain Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	345,060	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	5,821,426	0

Implementing Mechanism Indicator Information



Indicator Number	Label	2017
INVS_COMD	PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner	2
INVS_COMD	HIV Test Kits: Dollars planned (COP)/ spent (Actual)	547,441
INVS_COMD	HIV CD4 Tests: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV Viral Load: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	Condoms: Dollars planned (COP)/ spent (Actual)	0
INVS_COMD	HIV ARVs: Dollars planned (COP)/ spent (Actual)	5,573,985

Implementing Mechanism Details

Mechanism ID: 18379	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18380	Mechanism Name: Palladium
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID:	18380		
Mechanism Name:	Palladium		
Prime Partner Name:	Futures Group		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18387	Mechanism Name: FHI 360 Linkages for Care
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
G2G: No	Managing Agency:

Total All Funding Sources: 594,902	
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 594,902	
Funding Source	Funding Amount
GHP-USAID	594,902

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

Mechanism ID: 18387			
Mechanism Name: FHI 360 Linkages for Care			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	290,213	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	304,689	0

Implementing Mechanism Indicator Information

(No data provided.)

**Agency Information - Costs of Doing Business
U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Computers/IT Services			133,560	0	133,560	133,560
ICASS			533,481	259,589	533,481	793,070
Institutional Contractors			100,000	0	100,000	100,000
Management Meetings/Professional			30,484	0	30,484	30,484



Development						
Non-ICASS Administrative Costs			159,987	0	159,987	159,987
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel			37,706	0	37,706	37,706
USG Staff Salaries and Benefits - Internationally Recruited			219,219	936,583	219,219	1,155,802
USG Staff Salaries and Benefits - Locally Recruited			106,966	13,634	106,966	120,600
Total	0	0	1,321,403	1,209,806	1,321,403	2,531,209

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		0		3,111	0	3,111
ICASS		11,959		32,796	11,959	44,755
Institutional				0	0	0



Contractors						
Management Meetings/Professional Development		6,017		4,590	6,017	10,607
Non-ICASS Administrative Costs		0		1,090	0	1,090
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		14,684		12,304	14,684	26,988
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		34,759		59,770	34,759	94,529
Total	0	67,419	0	113,661	67,419	181,080

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline
-------------------------------	-----	-----------	-----------	------------------	-------	--



						Amount
Capital Security Cost Sharing		143,005		78,161	143,005	221,166
Computers/IT Services		92,111		14,670	92,111	106,781
ICASS		325,197		189,803	325,197	515,000
Institutional Contractors		108,868		169,615	108,868	278,483
Management Meetings/Professional Development		11,000		10,000	11,000	21,000
Non-ICASS Administrative Costs		38,864		0	38,864	38,864
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		94,857		26,433	94,857	121,290
USG Staff Salaries and Benefits - Internationally Recruited	487,500	476,960		0	964,460	964,460
USG Staff Salaries and Benefits - Locally Recruited		216,722		373,053	216,722	589,775
Total	487,500	1,507,584	0	861,735	1,995,084	2,856,819

U.S. Department of State



Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Capital Security Cost Sharing		132,700		0	132,700	132,700
ICASS		154,671		0	154,671	154,671
Institutional Contractors				0	0	0
Management Meetings/Professional Development		11,000		0	11,000	11,000
Non-ICASS Administrative Costs		16,420		0	16,420	16,420
Staff Program Travel		45,843		0	45,843	45,843
USG Staff Salaries and Benefits - Internationally Recruited		276,598		0	276,598	276,598
USG Staff Salaries and Benefits - Locally Recruited		380,168		0	380,168	380,168
Total	0	1,017,400	0	0	1,017,400	1,017,400



U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Applied Pipeline	Total	Total All Cost of Doing Business Categories and Applied Pipeline Amount
Institutional Contractors				0	0	0
Non-ICASS Administrative Costs		127,278		0	127,278	127,278
Peace Corps Volunteer Costs		677,479		0	677,479	677,479
Staff Program Travel		2,165		0	2,165	2,165
USG Staff Salaries and Benefits - Internationally Recruited				0	0	0
USG Staff Salaries and Benefits - Locally Recruited		192,523		0	192,523	192,523
Total	0	999,445	0	0	999,445	999,445